A prospective phase II, randomised multi-center trial of a biomodulatory treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with lung cancer, after platin failure (ModuLung).
Daniel Heudoble, Christian Schulz, Jürgen R. Fischer, Peter Staib, Thomas Wehler, Thomas Südhoff, Thomas Schichtl, Jochen Wilke, Joachim Hahn, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Tobias Pukrop, Wolfgang Herr, Swantje Held, Kristine Beckers, Gauthier Bouche, Albrecht Reichle. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Front. Pharmacol., 16 March 2021,doi.org/10.3389/fphar.2021.599598
